Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01660711 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Endeavor Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01660711 is a Phase 2 study that has completed, run by Endeavor Health. The registered enrollment target is 22 participants.
The verdict
NCT01660711, a Phase 2 study, has completed, sponsored by Endeavor Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of the study is to demonstrate that it is possible to administer chemotherapy prior to and following surgery for pancreatic cancer which is considered operable. The chemotherapy chosen is that which has been shown to be the most effective in treating metastatic disease, and the goal is both to investigate whether this is tolerable and also to investigate the efficacy of this approach in terms of disease response and survival.
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Irinotecan
- DRUG 5 Fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-07 |
| Est. Completion | 2018-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01660711
The ClinicalTrials.gov registry entry for NCT01660711 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Leucovorin is the first listed.
NCT01660711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01660711 about?
NCT01660711 is a clinical study titled "A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma". The purpose of the study is to demonstrate that it is possible to administer chemotherapy prior to and following surgery for pancreatic cancer which is considered operable. The chemotherapy chosen is that which has been shown to be the most effective in treating metastatic disease, and the goal is b...
What is the current status of trial NCT01660711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2012-07. Estimated completion is 2018-08-22.
What interventions are being tested in trial NCT01660711?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Irinotecan (DRUG), 5 Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT01660711?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.